DREAMS-3, a Phase III clinical study of Masitutide head-to-head semaglutide, achieved its primary endpoint
October 28, 2025
Source: drugdu
82
On October 27, Innovent Biologics announced that the fourth Phase III clinical study (DREAMS-3) of its glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, Mastolide (development code: IBI362), achieved its primary endpoint. The results demonstrated that among Chinese subjects with type 2 diabetes and obesity, 48.0% of subjects in the Mastolide group achieved HbA1c <7.0% and a 10% or greater weight loss from baseline at week 32, superior to the 21.0% in the semaglutide group (P < 0.0001). Furthermore, at week 32, the mean changes in HbA1c from baseline were 2.03% and 1.84% in the Mastolide and semaglutide groups, respectively, and the mean percentage reductions in weight from baseline were 10.29% and 6.00%, respectively (both P < 0.05).
Source：https://finance.eastmoney.com/a/202510273544625429.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
